Hee Jin Lee

List of Publications by Year
in descending order

98 papers	4,569 citations	147566 31 h-index	114278 63 g-index
106 all docs	106 docs citations	106 times ranked	10491 citing authors

#	Article	IF	Citations
1	Phenotypic Differences of CD103<sup>+</sup> Tissue-Resident Memory T Cells Associated with Various Cancers. Pathobiology, 2022, 89, 116-126.	1.9	0
2	Oncologic outcomes of immediate breast reconstruction in young women with breast cancer receiving neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2022, 191, 345-354.	1.1	4
3	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precision Oncology, 2022, 6, e2000368.	1.5	9
4	Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer. Cancer Research and Treatment, 2022, , .	1.3	0
5	The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer. Cancer Research and Treatment, 2022, 54, 1111-1120.	1.3	1
6	Factors Associated with Successful Smoking Cessation in Outpatient Smokers after the Initiation of National Smoking Cessation Support Program. Korean Journal of Family Practice, 2022, 12, 93-100.	0.1	0
7	Artificial intelligence (AI)â€"powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2022, 40, 595-595.	0.8	5
8	Prediction of tumor metastasis <i>via</i> extracellular vesicles-treated platelet adhesion on a blood vessel chip. Lab on A Chip, 2022, 22, 2726-2740.	3.1	5
9	Standardized Pathology Report for Breast Cancer. Journal of Breast Cancer, 2021, 24, 1.	0.8	9
10	Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. Journal of Breast Cancer, 2021, 24, 359.	0.8	4
11	Targeted eicosanoids profiling reveals a prostaglandin reprogramming in breast Cancer by microRNA-155. Journal of Experimental and Clinical Cancer Research, 2021, 40, 43.	3.5	15
12	Standardized pathology report for breast cancer. Journal of Pathology and Translational Medicine, 2021, 55, 1-15.	0.4	3
13	Comparison of the Imaging Features of Lobular Carcinoma In Situ and Invasive Lobular Carcinoma of the Breast. Journal of the Korean Society of Radiology, 2021, 82, 1231.	0.1	0
14	Abstract PS13-07: Neoadjuvant adriamycin plus cyclophosphamide followed by docetaxel (AC4-D4) vs 5-fluorouracil, epirubicin plus cyclophosphamide followed by docetaxel (FEC3-D3) in stage II or III operable breast cancer : Randomized phase III neo-shorter trial (NCT02001506). , 2021, , .		0
15	A New Human Leukocyte Antigen Typing Algorithm Combined With Currently Available Genotyping Tools Based on Next-Generation Sequencing Data and Guidelines to Select the Most Likely Human Leukocyte Antigen Genotype. Frontiers in Immunology, 2021, 12, 688183.	2.2	8
16	Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability. Journal of Breast Cancer, 2021, 24, 266.	0.8	13
17	A DNA Topoisomerase II Inhibitor Results in Ex Vivo Differentiation of THP-1 Cells and Activation of Dendritic Cells. Anticancer Research, 2021, 41, 6087-6094.	0.5	0
18	Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Cancers, 2021, 13, 6267.	1.7	7

#	Article	IF	Citations
19	Is asymptomatic surveillance beneficial after standard treatment? A 10‑year survival analysis of recurrent BC patients by detection method of recurrence. Breast Journal, 2020, 26, 556-559.	0.4	1
20	Development and Validation of a Next-Generation Sequencing‑Based Multigene Assay to Predict the Prognosis of Estrogen Receptor‑Positive, HER2-Negative Breast Cancer. Clinical Cancer Research, 2020, 26, 6513-6522.	3.2	6
21	Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. Scientific Reports, 2020, 10, 17466.	1.6	11
22	Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. Anticancer Research, 2020, 40, 5883-5893.	0.5	1
23	Three-Dimensional Human Liver-Chip Emulating Premetastatic Niche Formation by Breast Cancer-Derived Extracellular Vesicles. ACS Nano, 2020, 14, 14971-14988.	7.3	63
24	T cell receptor repertoires of ex vivo‑expanded tumor-infiltrating lymphocytes from breast cancer patients. Immunologic Research, 2020, 68, 233-245.	1.3	1
25	Prediction of prognostic signatures in triple-negative breast cancer based on the differential expression analysis via NanoString nCounter immune panel. BMC Cancer, 2020, 20, 1052.	1.1	10
26	Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer. Cancer Immunology, Immunotherapy, 2020, 69, 2381-2391.	2.0	5
27	Streamlined selection of cancer antigens for vaccine development through integrative multi-omics and high-content cell imaging. Scientific Reports, 2020, 10, 5885.	1.6	5
28	RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics, 2020, 10, 7974-7992.	4.6	42
29	CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy. Cancer Immunology Research, 2020, 8, 912-925.	1.6	53
30	Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer. Anticancer Research, 2020, 40, 1883-1890.	0.5	23
31	Effectiveness of transfer learning for enhancing tumor classification with a convolutional neural network on frozen sections. Scientific Reports, 2020, 10, 21899.	1.6	42
32	The Impact of Androgen Receptor and Histone Deacetylase 1 Expression on the Prognosis of Ductal Carcinoma *In Situ*. Journal of Breast Cancer, 2020, 23, 610.	0.8	4
33	Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer. American Journal of Cancer Research, 2020, 10, 2878-2894.	1.4	6
34	Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis. Modern Pathology, 2019, 32, 70-80.	2.9	67
35	Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells. Oncogene, 2019, 38, 6382-6398.	2.6	28
36	EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer. Cancers, 2019, 11, 1067.	1.7	29

#	Article	IF	Citations
37	Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer. Anticancer Research, 2019, 39, 3111-3119.	0.5	12
38	Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer. Annals of Surgical Oncology, 2019, 26, 2166-2174.	0.7	12
39	Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Journal of Pathology and Translational Medicine, 2019, 53, 180-187.	0.4	18
40	Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer. Immunologic Research, 2019, 67, 469-477.	1.3	1
41	Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers. Cancer Research and Treatment, 2019, 51, 80-89.	1.3	22
42	Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model. Cancer Letters, 2018, 428, 127-138.	3.2	19
43	microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer. Oncogene, 2018, 37, 2982-2991.	2.6	95
44	Predicting the level of tumor‐infiltrating lymphocytes in patients with triple‐negative breast cancer: Usefulness of breast MRI computer‐aided detection and diagnosis. Journal of Magnetic Resonance Imaging, 2018, 47, 760-766.	1.9	24
45	CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer. In Vivo, 2018, 32, 1561-1569.	0.6	36
46	<i>FcrR3A</i>-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment. Journal of Breast Cancer, 2018, 21, 45.	0.8	0
47	A Clinicopathologic Study of 220 Cases of Pulmonary Sclerosing Pneumocytoma in Korea: A Nationwide Survey. Journal of Pathology and Translational Medicine, 2018, , .	0.4	0
48	Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 381-389.	1.4	31
49	A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2⁻ early breast cancer. Scientific Reports, 2017, 7, 45554.	1.6	26
50	ADAR1 expression is associated with tumour-infiltrating lymphocytes in triple-negative breast cancer. Tumor Biology, 2017, 39, 101042831773481.	0.8	18
51	Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. PLoS ONE, 2017, 12, e0182786.	1.1	91
52	Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer. Oncotarget, 2017, 8, 113345-113359.	0.8	61
53	Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)â€"Positive Breast Cancers. Cancer Research and Treatment, 2017, 49, 313-321.	1.3	11
54	Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. Cancer Research and Treatment, 2017, 49, 399-407.	1.3	97

#	Article	IF	Citations
55	Significance of EZH2 expression in canine mammary tumors. BMC Veterinary Research, 2016, 12, 164.	0.7	8
56	Expression of <scp>FOXM</scp>1 and related proteins in breast cancer molecular subtypes. International Journal of Experimental Pathology, 2016, 97, 170-177.	0.6	43
57	Tumor apparent diffusion coefficient as an imaging biomarker to predict tumor aggressiveness in patients with estrogen-receptor-positive breast cancer. NMR in Biomedicine, 2016, 29, 1070-1078.	1.6	37
58	Frequency of <scp>MED</scp>12 mutations in phyllodes tumors: Inverse correlation with histologic grade. Genes Chromosomes and Cancer, 2016, 55, 495-504.	1.5	24
59	Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumorâ€‌infiltrating lymphocytes (TILs) in breast cancer. Pathology International, 2016, 66, 202-209.	0.6	19
60	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	13.7	1,760
61	MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer. Breast Cancer Research and Treatment, 2016, 156, 597-606.	1.1	21
62	Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. Cancer Chemotherapy and Pharmacology, 2016, 78, 685-695.	1.1	20
63	An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctyes. American Journal of Clinical Pathology, 2016, 146, 137-144.	0.4	22
64	Correlation Between MRI and the Level of Tumor-Infiltrating Lymphocytes in Patients With Triple-Negative Breast Cancer. American Journal of Roentgenology, 2016, 207, 1146-1151.	1.0	37
65	Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. Journal of Clinical Pathology, 2016, 69, 422-430.	1.0	117
66	The Role of High-Resolution Magic Angle Spinning 1H Nuclear Magnetic Resonance Spectroscopy for Predicting the Invasive Component in Patients with Ductal Carcinoma In Situ Diagnosed on Preoperative Biopsy. PLoS ONE, 2016, 11, e0161038.	1.1	23
67	Endoplasmic reticulum stress induces secretion of high-mobility group proteins and is associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. Oncotarget, 2016, 7, 59957-59964.	0.8	19
68	Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. Oncotarget, 2016, 7, 30119-30132.	0.8	62
69	Activation of the PERK-eIF2Î± Pathway Is Associated with Tumor-infiltrating Lymphocytes in HER2-Positive Breast Cancer. Anticancer Research, 2016, 36, 2705-11.	0.5	13
70	Prognostic Factors for Distant Metastasis in Patients with Locoregional Recurrence after Mastectomy. Journal of Breast Cancer, 2015, 18, 279.	0.8	5
71	Dysregulation of X Chromosome Inactivation in High Grade Ovarian Serous Adenocarcinoma. PLoS ONE, 2015, 10, e0118927.	1.1	18
72	Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers. PLoS ONE, 2015, 10, e0137885.	1.1	20

#	ARTICLE	IF	CITATIONS
73	Cancer-Testis Antigen Expression in Serous Endometrial Cancer with Loss of X Chromosome Inactivation. PLoS ONE, 2015, 10, e0137476.	1.1	12
74	Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis. Oncology, 2015, 89, 337-344.	0.9	27
75	Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Breast Cancer Research and Treatment, 2015, 151, 619-627.	1.1	58
76	Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. American Journal of Clinical Pathology, 2015, 144, 278-288.	0.4	103
77	Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab. American Journal of Clinical Pathology, 2015, 144, 570-578.	0.4	52
78	High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 701-709.	1.4	25
79	Prognostic factors and outcome analysis of salivary duct carcinoma. Auris Nasus Larynx, 2015, 42, 472-477.	0.5	24
80	Bioinformatic and metabolomic analysis reveals miR-155 regulates thiamine level in breast cancer. Cancer Letters, 2015, 357, 488-497.	3.2	36
81	Correlations Between Molecular Subtypes and Pathologic Response Patterns of Breast Cancers After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2015, 22, 392-400.	0.7	15
82	Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia-Mutated Proteins in Epithelial Ovarian Carcinoma: Their Expression and Clinical Significance. Anticancer Research, 2015, 35, 3909-16.	0.5	5
83	Positive Expression of Insulin-Like Growth Factor-1 Receptor Is Associated with a Positive Hormone Receptor Status and a Favorable Prognosis in Breast Cancer. Journal of Breast Cancer, 2014, 17, 113.	0.8	25
84	Low Prognostic Implication of Fibroblast Growth Factor Family Activation in Triple-negative Breast Cancer Subsets. Annals of Surgical Oncology, 2014, 21, 1561-1568.	0.7	55
85	Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Research and Treatment, 2014, 145, 615-623.	1.1	50
86	High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Modern Pathology, 2014, 27, 1212-1222.	2.9	220
87	Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes. Cancer Letters, 2014, 353, 232-241.	3.2	61
88	Prognostic Significance of Biallelic Loss of *PTEN* in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 940-946.	0.2	14
89	MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting. Pathology Research and Practice, 2014, 210, 494-500.	1.0	9
90	Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. F1000Research, 2014, 3, 198.	0.8	40

#	Article	IF	Citations
91	ROS1 Receptor Tyrosine Kinase, a Druggable Target, is Frequently Overexpressed in Non-Small Cell Lung Carcinomas Via Genetic and Epigenetic Mechanisms. Annals of Surgical Oncology, 2013, 20, 200-208.	0.7	46
92	Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells. Modern Pathology, 2013, 26, 1123-1131.	2.9	59
93	Combined Loss of E-cadherin and Aberrant Î²-Catenin Protein Expression Correlates With a Poor Prognosis for Small Intestinal Adenocarcinomas. American Journal of Clinical Pathology, 2013, 139, 167-176.	0.4	34
94	Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer, 2013, 16, 32.	0.8	112
95	HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 521-530.	1.4	25
96	Comparison of genetic and epigenetic alterations at 11 tumor suppressor loci in pulmonary sclerosing hemangioma and adenocarcinoma. Experimental Lung Research, 2011, 37, 344-353.	0.5	11
97	Detection of *BRAF* Mutations in Thyroid Nodules by Allele-Specific PCR Using a Dual Priming Oligonucleotide System. American Journal of Clinical Pathology, 2010, 133, 802-808.	0.4	45
98	Pulmonary Benign Metastasizing Leiomyoma Associated With Intravenous Leiomyomatosis of the Uterus: Clinical Behavior and Genomic Changes Supporting A Transportation Theory. International Journal of Gynecological Pathology, 2008, 27, 340-345.	0.9	66